223 related articles for article (PubMed ID: 32978089)
1. Capicua in Human Cancer.
Kim JW; Ponce RK; Okimoto RA
Trends Cancer; 2021 Jan; 7(1):77-86. PubMed ID: 32978089
[TBL] [Abstract][Full Text] [Related]
2. Capicua suppresses YAP1 to limit tumorigenesis and maintain drug sensitivity in human cancer.
Kim JW; Luck C; Wu W; Ponce RK; Lin YK; Gupta N; Okimoto RA
Cell Rep; 2022 Oct; 41(1):111443. PubMed ID: 36198276
[TBL] [Abstract][Full Text] [Related]
3. Comparative transcriptome analysis of isogenic cell line models and primary cancers links capicua (CIC) loss to activation of the MAPK signalling cascade.
LeBlanc VG; Firme M; Song J; Chan SY; Lee MH; Yip S; Chittaranjan S; Marra MA
J Pathol; 2017 Jun; 242(2):206-220. PubMed ID: 28295365
[TBL] [Abstract][Full Text] [Related]
4. The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer.
Simón-Carrasco L; Jiménez G; Barbacid M; Drosten M
Cell Cycle; 2018; 17(6):702-711. PubMed ID: 29578365
[TBL] [Abstract][Full Text] [Related]
5. SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker.
Kolukula VK; Sahu G; Wellstein A; Rodriguez OC; Preet A; Iacobazzi V; D'Orazi G; Albanese C; Palmieri F; Avantaggiati ML
Oncotarget; 2014 Mar; 5(5):1212-25. PubMed ID: 24681808
[TBL] [Abstract][Full Text] [Related]
6. The Tumor Suppressor CIC Directly Regulates MAPK Pathway Genes via Histone Deacetylation.
Weissmann S; Cloos PA; Sidoli S; Jensen ON; Pollard S; Helin K
Cancer Res; 2018 Aug; 78(15):4114-4125. PubMed ID: 29844126
[TBL] [Abstract][Full Text] [Related]
7. MiR-1307 influences the chemotherapeutic sensitivity in ovarian cancer cells through the regulation of the CIC transcriptional repressor.
Zhou Y; Wang M; Shuang T; Liu Y; Zhang Y; Shi C
Pathol Res Pract; 2019 Oct; 215(10):152606. PubMed ID: 31500928
[TBL] [Abstract][Full Text] [Related]
8. Negative MAPK-ERK regulation sustains CIC-DUX4 oncoprotein expression in undifferentiated sarcoma.
Lin YK; Wu W; Ponce RK; Kim JW; Okimoto RA
Proc Natl Acad Sci U S A; 2020 Aug; 117(34):20776-20784. PubMed ID: 32788348
[TBL] [Abstract][Full Text] [Related]
9. Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer.
Lian B; Pei YC; Jiang YZ; Xue MZ; Li DQ; Li XG; Zheng YZ; Liu XY; Qiao F; Sun WL; Ling H; He M; Yao L; Hu X; Shao ZM
Theranostics; 2020; 10(24):11092-11109. PubMed ID: 33042272
[No Abstract] [Full Text] [Related]
10. TRIM25 promotes Capicua degradation independently of ERK in the absence of ATXN1L.
Wong D; Sogerer L; Lee SS; Wong V; Lum A; Levine AB; Marra MA; Yip S
BMC Biol; 2020 Oct; 18(1):154. PubMed ID: 33115448
[TBL] [Abstract][Full Text] [Related]
11. A double-edged sword: The world according to Capicua in cancer.
Tanaka M; Yoshimoto T; Nakamura T
Cancer Sci; 2017 Dec; 108(12):2319-2325. PubMed ID: 28985030
[TBL] [Abstract][Full Text] [Related]
12. Making heads or tails - the emergence of capicua (CIC) as an important multifunctional tumour suppressor.
Wong D; Yip S
J Pathol; 2020 Apr; 250(5):532-540. PubMed ID: 32073140
[TBL] [Abstract][Full Text] [Related]
13. Dual-specificity phosphatases: therapeutic targets in cancer therapy resistance.
Zandi Z; Kashani B; Alishahi Z; Pourbagheri-Sigaroodi A; Esmaeili F; Ghaffari SH; Bashash D; Momeny M
J Cancer Res Clin Oncol; 2022 Jan; 148(1):57-70. PubMed ID: 34981193
[TBL] [Abstract][Full Text] [Related]
14. Rapid Dynamics of Signal-Dependent Transcriptional Repression by Capicua.
Keenan SE; Blythe SA; Marmion RA; Djabrayan NJ; Wieschaus EF; Shvartsman SY
Dev Cell; 2020 Mar; 52(6):794-801.e4. PubMed ID: 32142631
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of super enhancer-derived noncoding RNAs in human cancer.
Wang Y; Nie H; He X; Liao Z; Zhou Y; Zhou J; Ou C
Theranostics; 2020; 10(24):11049-11062. PubMed ID: 33042269
[TBL] [Abstract][Full Text] [Related]
16. Surmounting cancer drug resistance: New insights from the perspective of N
Li B; Jiang J; Assaraf YG; Xiao H; Chen ZS; Huang C
Drug Resist Updat; 2020 Dec; 53():100720. PubMed ID: 32892147
[TBL] [Abstract][Full Text] [Related]
17. CIC protein instability contributes to tumorigenesis in glioblastoma.
Bunda S; Heir P; Metcalf J; Li ASC; Agnihotri S; Pusch S; Yasin M; Li M; Burrell K; Mansouri S; Singh O; Wilson M; Alamsahebpour A; Nejad R; Choi B; Kim D; von Deimling A; Zadeh G; Aldape K
Nat Commun; 2019 Feb; 10(1):661. PubMed ID: 30737375
[TBL] [Abstract][Full Text] [Related]
18. ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition.
Wang B; Krall EB; Aguirre AJ; Kim M; Widlund HR; Doshi MB; Sicinska E; Sulahian R; Goodale A; Cowley GS; Piccioni F; Doench JG; Root DE; Hahn WC
Cell Rep; 2017 Feb; 18(6):1543-1557. PubMed ID: 28178529
[TBL] [Abstract][Full Text] [Related]
19. Capicua (CIC) mutations in gliomas in association with MAPK activation for exposing a potential therapeutic target.
Darabi S; Xiu J; Samec T; Kesari S; Carrillo J; Aulakh S; Walsh KM; Sengupta S; Sumrall A; Spetzler D; Glantz M; Demeure MJ
Med Oncol; 2023 Jun; 40(7):197. PubMed ID: 37291277
[TBL] [Abstract][Full Text] [Related]
20. Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance.
Roy Burman D; Das S; Das C; Bhattacharya R
Mol Biol Rep; 2021 Jan; 48(1):897-914. PubMed ID: 33400075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
